New Phase 3 Data: Dupilumab Reduces Itch Severity, Hive Count, and Other CSU Symptoms
Dupilumab (Dupixent, Sanofi and Regeneron) reduces itch and urticaria activity scores in patients with chronic spontaneous urticaria (CSU), a new study confirms. In the confirmatory phase 3 study (LIBERTY-CUPID Study C), dupilumab met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve CSU receiving background therapy with antihistamines. Specifically, […]